Magnesium Isoglycyrrhizinate Combined with Lipid-lowering Therapy for Nonalcoholic Fatty Hepatitis and Its Effect on Liver Function

Objective To probe into magnesium isoglycyrrhizinate combined with lipid-lowering efficacy in the treatment of nonalcoholic fatty hepatitis and its effect on liver function.Methods 92 patients with cases non-alcoholic fatty hepatitis in our hospital during May 2011-October 2014 were selected as the research object:control group was given lipid based comprehensive treatment,which the observation group received comprehensive treatment combined with magnesium isoglycyrrhizinate.PC III,C- I V,HA and ALT,AST,TBIL,-GT and other indexes of hepatic fibrosis gamma of two groups before and after treatment were compared.Results Two groups before treatment,difference of indexes of hepatic fibrosis had no statistical significance(P 0.05);after the treatment,the index PC III,C- I V,HA etc of observation group were significantly lower,difference were statistical significance compared with before treatment(P 0.05),and control group after treatment between group was statistics significance(P 0.05).Before treatment,differences of liver function index,ALT,AST,TBIL,-GT and other gamma between groups showed no statistical significance(P 0.05),after the treatment,differences between two groups were statistically significant(P 0.05);within group comparison,the two groups before and after treatment of each index were statistically significant(P 0.05).Conclusion Magnesium isoglycyrrhizinate,which can protect the liver cells,combined with lipid-lowering treatment for patients with NASH can effectively inhibit fibrosis of liver cells,promote liver function recovery,so it has high application value.